Sample characteristics of the study population: The authors did not mention that patients who had CBVD recurrence reported substance use significantly less frequently than those who did not have a CBVD recurrence. Predictors of cerebrovascular recurrence: The authors should list that lipid-lowering medications were associated with an increased risk of CBVD recurrence in Model II. Line 177: This sentence seems incomplete, is the word ''significant'' missing between the words ''statistically predictors''? Discussion:
Overall, since the present study included all CBVD as listed in the Introduction and Methodology, then discussion also needs to include references to previous studies which investigated other listed CBVD and not only stroke or its subtypes. Also, when discussing results of other studies, explicitly state for which CBVD was an increased or decreased risk found in that study (instead of e.g. ''increased risk of CBVD recurrence'' if a study investigated ischemic stroke use ''increased risk of ischemic stroke''). Line 198: You state that there was a higher depression rate (73.6% vs. 69.7%) between those who had and those who did not have CBVD recurrence. Since this study included only participants diagnosed with a depressive disorder, this sentence is unclear. Do the authors actually refer to depression severity or symptoms? Lines 210-211: As authors stated in Methodology, they collected information on prescribed medications. When the authors state ''anticoagulant use'', they should note that there is always a question of medication compliance in patients. In the same paragraph authors correctly refer to ''antipsychotic prescription''. Please correct this. In Model II, authors found that prescription of lipid-lowering medication was associated with a significantly increased risk for CBVD recurrence. One of the studies which authors discuss (Oza et al.) recommends use of lipid-lowering medication because of a lower risk of recurrent stroke. The authors should discuss this finding. Lines 226-229: Another limitation of this study is that non-CBVD circulatory diseases as comorbidities were not presented by disease. Line 229: It is not appropriate to take together these numbers since they are referring to very different groups of disorders. Present the percentage of patients with comorbidities separately for diabetes and non-CBVD circulatory diseases. Limitations must necessarily include that the length/duration of depression before the participants experienced CBVD recurrence was not presented. Limitations should include no presented data on other possible factors which could predict CBVD recurrence, including obesity, smoking, alcohol use (authors used ''substance use'' as a covariate), hyperlipidemia, antiplatelet medications. Conclusion: Make it clear that patients with depression and CBVD are actually patients who were diagnosed with depression after they had CBVD. Tables 1 and 2: Instead of CVD use CBVD, same as throughout the manuscript. Table 1: Throughout the Table and its footnote, use and list letters in order in which they appear in the Table (a-f). Spell out abbreviations in the footnote. Bottom of page 9, I am unsure why anticagulation predicts underlying severity of disease. Do you mean that they have had more heamorrhages on anticoagulants, which are more severe? Please rephrase this as it does not currently make sense scientifically. Response: We accept this comment, and have rephrased the text in question to make it more clear as follows: ' We found that anticoagulant prescription was an independent predictor of adverse cerebrovascular outcomes, which is consistent with a previous finding of an association between anticoagulants and secondary hemorrhagic stroke11 '. (Line 248-250 on Page 12) Page 9.,lines 216-219. I think it is too strong to suggest a different mechanism here, this section should be toned down and rephrased. Response: Many thanks for the suggestion. We have toned down and rephrased this section as follows: ' This raises the possibility that addressing target symptoms such as psychosis or agitation related to depression and CBVD might be associated with benefits that outweigh potential risks; however, this clearly requires further investigation'. (Line 254-256 on Page 13) The next paragraph, lines 226-229, is very hard to follow. can you please consider what you are trying to say here and rephrase this please Response: Thanks for the advice. We have rephrased this paragraph to make it more clear as follows: ' In line with previous studies13-15, we found higher prevalences of other comorbidities including diabetes (0.7% higher) and non-CBVD circulatory diseases (4.1% higher) in the cohort with recurrent CBVD than those without CBVD recurrence; however, these were not independent in the fully-adjusted model, and the measure of global health status in the HoNOS showed a stronger and more consistent association. '. (Line 264-269 on Page 13)
The strengths and limitations section was strong Response: Thank you so much for your comments.
Reviewer: 2
Reviewer comments for the manuscript entitled ''Predictors of cerebrovascular event reoccurrence in patients with depression and cerebrovascular disease: A representative cohort study'' Overall, the English language of this manuscript needs improvement. Response: Thanks for your suggestion. The language of this revised manuscript has been further reviewed and improved by a native English speaking co-author.
Title: Please consider changing the title to ''Predictors of cerebrovascular event reoccurrence in patients with depression: A retrospective cohort study''. Explanation: the title already mentions reoccurrence, so it is not necessary to repeat cerebrovascular disease twice. The study is a certainly a retrospective cohort study, and whether it is representative that is another question. Response: We accept this comment and have changed the title to 'Predictors of cerebrovascular event reoccurrence in patients with depression: A retrospective cohort study'. (Line1-2 on Page 1) Abstract: Objectives are unclear with regards to the cohort of patients. It is not stated clearly that these patients experienced or were diagnosed with depression after a CBVD. Response: We have rephrased the statement as follows: ' To identify predictors of recurrent cerebrovascular morbidity in a cohort of patients with depression and a cerebrovascular disease (CBVD) history.' (Line29-30 on Page 2)
Methods:
In a cohort study such as this, the first criterion for choosing participants is always listed first (depression), and then the second criterion for choosing participants is listed (cerebrovascular disease). Please correct this issue and use correctly consistently throughout the entire manuscript. The sentence ''Using depression diagnosis as index date we followed patients until first hospitalized CBVD.'' can be more precise if you emphasized that this first hospitalized CBVD is actually CBVD recurrence. Response: Many thanks. We have corrected the first issue you mentioned as follows: ' We identified patients with previously hospitalised depressive disorder and CBVD ascertained between 2008 and 2017 ……' and used correctly consistently throughout the entire manuscript. In order to make it clear, we have changed the sentence to ' Using depression diagnosis as the index date we followed patients until first hospitalised CBVD recurrence.' (Line31-34 on Page 2) Results: As all numbers are given with decimals, instead of 57% of women state 56.6%. Consider adding P values in brackets. Response: We have provided all numbers with decimals and have added P values in brackets as follows: ' Of 1292 patients with depression and CBVD (mean age 75.6 years; 56.6% female), 181 (14.0%) experienced fatal/non-fatal CBVD recurrence during a median follow-up duration of 1.66 years. In multivariate Cox regression models, CBVD recurrence was predicted by older age (HR, 1.02; 95 % CI, 1.01-1.04) (P=0.002), physical health problems (HR, 2.47; 95 % CI, 1.45-4.19) (P=0.001), and anticoagulant medication (HR, 1.40; 95 % CI, 1.01-1.93) (P=0.041). Neither depression severity, mental health symptoms, functional status, nor psychotropic prescribing were significantly associated with CBVD recurrence.' (Line38-44 on Page 2) Strengths and limitations of this study: It is important to add here also that this study did not differentiate between types of CBVD. Response: We have added the following text: ' Outcome ascertainment was limited to ICD-10 diagnoses applied to hospitalisation episodes, and types of CBVD could not be differentiated.' (Line56-57 on Page 3)
Introduction:
The research question of this study is very important, and authors should consider adding information on factors identified in previous studies as predictors of CBVD recurrence in patients with CBVD and depression, to adequately show the mentioned gap in evidence. Response: Thank you for your advice. We have added information as follows: ' Few studies have explored stroke recurrence in stroke survivors with depression6-9, and these have reported inconsistent results: three studies6,8,9 found that the presence of depression was associated with an increased hazard for stroke recurrence, while Ayerbe et al7 found that depression at 3 months after stroke was not associated with higher risk of total stroke recurrence over a 5-year follow-up (hazard ratio (HR): 0.98). Furthermore, although a number of previous studies have reported findings on possible risk factors such as older age8, physical illness10, medications9,11,12 and comorbidities13-15 predicting first or recurrent CBVD in community samples, few have investigated prediction in people with both depression and CBVD history, despite the likelihood that this is a high risk group. ' (Line68-76 on Page 4)
Methods:
Participants: It is necessary to list all ICD-10 codes used for depressive disorder diagnosis. Response: We have listed all ICD-10 codes used for depressive disorder diagnosis in the bracket as follows: ' F32x and F33x ICD-10 codes'. (Line99 on Page 5) Participants, Outcomes: Authors state that they included all patients who received a depressive disorder diagnosis up to 31st December 2017. They also state that linkage with HES was used to ascertain CBVD re-hospitalization until March 2017. It is unclear what happened with those participants who were diagnosed with depression after March 2017, why were they included if CBVD re-hospitalization was not checked for them? Response: We apologise that this was not sufficiently clear in the manuscript. Those patients who were diagnosed with depression after March 2017 were excluded because CBVD re-hospitalization was not checked for them. We have stated that in the section of Outcomes as follows: ' For outcomes, the linkage with HES was used to ascertain CBVD re-hospitalisation until March 2017. A hospitalised non-fatal CBVD recurrence was defined when an ICD-10 code of I60x-69x was recorded as a primary or secondary diagnosis for a hospital admission. Fatal CBVD recurrence was ascertained if an underlying cause of death with an ICD-10 code of I60x-69x was recorded on the patient's death certificate. The two outcomes were combined to define CBVD recurrence and the sample was followed until the first fatal or non-fatal CBVD event, death from any other cause or a censoring point on March 31st 2017'. (Line104-110 on Page 5-6)
Predictors: When referring to Health of the Nation Outcome Scales (HoNOS), please add the time window for extraction of these scores compared to index date. It is stated in Tables' footnotes, however it should be included in Methodology too. Response: We have added the time window for extraction of these scores compared to index date in Methodology as follows: ' Mental, physical and functional problems were identified via the Health of the Nation Outcome Scales (HoNOS) six months before and after the index date'. (Line121-122 on Page 6) Please explain the rationale behind the time window (''from 6 months before to 6 months after the index date'') used for ascertaining medications which patients received. Response: This is an important point. In clarification, we added the following to the methods section: ' The six-month window around the index date was chosen, as medication prescription is not always recorded close to the index date in routinely collected data, and ascertainment in this window has provided good predictive validity in previous studies from this data source 18,26,27'(Line140-143 on Page 6-7)
Please explain why the duration of depression was not included as a predictor of events in this study. Response: Because of the limited time-window captured comprehensively in the database (representation of all SLaM services since 2006; some longer-duration records for particular services), and the naturally fluctuating course of depression, we felt that its duration could not be adequately captured. We have included this issue in the Limitations section.
Statistical analysis: Authors need to define hazard ratios and corresponding 95% confidence intervals.
Response: We have defined hazard ratios and corresponding 95% confidence intervals as follows: ' Cox proportional hazard ratios (HRs) and 95% confidence intervals (CI) were calculated for potential risk factors affecting time to the outcome of interest (i.e. first non-fatal (hospitalised) or fatal CBVD event).' (Line150-152 on Page 7)
Results: When reporting means followed by brackets with SD, input ''SD'' in the brackets. Response: We have inputted 'SD' in the brackets. (Line172 on Page 8) Sample characteristics of the study population: The authors did not mention that patients who had CBVD recurrence reported substance use significantly less frequently than those who did not have a CBVD recurrence. Response: We have mentioned it as follows: 'Patients who suffered from CBVD recurrence …… ,but less frequently recorded with substance use …...' (Line180-181 on Page 8)
Predictors of cerebrovascular recurrence: The authors should list that lipid-lowering medications were associated with an increased risk of CBVD recurrence in Model II. Response: We have now listed it as follows: 'In models adjusted for age, gender, ethnic group, cohabiting status, deprivation index, severity of depression and physical health problems (Model 2), ……lipid-lowering medications were associated with a higher risk of CBVD recurrence'(Line198-199 on Page 10) Line 177: This sentence seems incomplete, is the word 'significant' missing between the words 'statistically predictors'? Response: We have inserted the missing word 'significant' between the words 'statistically predictors'. (Line201 on Page 10)
Discussion:
Overall, since the present study included all CBVD as listed in the Introduction and Methodology, then discussion also needs to include references to previous studies which investigated other listed CBVD and not only stroke or its subtypes. Also, when discussing results of other studies, explicitly state for which CBVD was an increased or decreased risk found in that study (instead of e.g. ''increased risk of CBVD recurrence'' if a study investigated ischemic stroke use ''increased risk of ischemic stroke''). Response: Unfortunately, after careful searching, we have found no published studies investigating other listed CBVD other than stroke or its subtypes. We have explicitly stated for which CBVD was an increased or decreased risk found in that study. (Page12-13) Line 198: You state that there was a higher depression rate (73.6% vs. 69.7%) between those who had and those who did not have CBVD recurrence. Since this study included only participants diagnosed with a depressive disorder, this sentence is unclear. Do the authors actually refer to depression severity or symptoms? Response: Yes, we referred it to depression severity. We've decided to drop this text because we felt that there was no need to highlight Table 1 associations that weren't independently demonstrated in Table 2 .
Lines 210-211: As authors stated in Methodology, they collected information on prescribed medications. When the authors state ''anticoagulant use'', they should note that there is always a question of medication compliance in patients. In the same paragraph authors correctly refer to ''antipsychotic prescription''. Please correct this. Response: We have changed 'anticoagulant use' to 'anticoagulant prescription', although have also sought to clarify throughout that medication is that 'recorded', as we were not using a prescribing database to ascertain this. (Line225/248 on Page 12) In Model II, authors found that prescription of lipid-lowering medication was associated with a significantly increased risk for CBVD recurrence. One of the studies which authors discuss (Oza et al.) recommends use of lipid-lowering medication because of a lower risk of recurrent stroke. The authors should discuss this finding. Response: Thank you for this suggestion. We have discussed it as follows: ' Oza et al.14 recommended use of lipid-lowering medication to lower the risk of recurrent stroke; however, we found that lipid-lowering medication was if anything associated with a significantly increased risk for CBVD recurrence in Model II, which might be explained by a previous finding that 5-year use of statin therapy increased the risk of hemorrhagic stroke39.' (Line261-264 on Page 13) Lines 226-229: Another limitation of this study is that non-CBVD circulatory diseases as comorbidities were not presented by disease. Response: We have added this to the Limitations section as follows: '…… non-CBVD circulatory diseases as comorbidities were also not characterised into specific conditions.'( Line277-281 on Page 13) Line 229: It is not appropriate to take together these numbers since they are referring to very different groups of disorders. Present the percentage of patients with comorbidities separately for diabetes and non-CBVD circulatory diseases. Response: We accept this point. We have presented the percentage of patients with comorbidities separately for diabetes and non-CBVD circulatory diseases as follows: ' …… we found higher prevalences of other comorbidities including diabetes (0.7% higher) and non-CBVD circulatory diseases (4.1% higher) in the cohort with recurrent CBVD than those without CBVD recurrence; however, these were not independent in the fully-adjusted model, and the measure of global health status in the HoNOS showed a stronger and more consistent association. '( Line265-269 on Page 13) Limitations must necessarily include that the length/duration of depression before the participants experienced CBVD recurrence was not presented. Response: We have included it in Limitations section as follows: ' Third, other potential risk factors for outcomes of interest were not directly captured, such as onset/duration of depression……' (Line278-279 on Page 13) Limitations should include no presented data on other possible factors which could predict CBVD recurrence, including obesity, smoking, alcohol use (authors used ''substance use'' as a covariate), hyperlipidemia, antiplatelet medications. Response: We have amended the Limitations section as suggested to the following text: ' Third, other potential risk factors for outcomes of interest were not directly captured, such as onset/duration of depression, obesity, smoking, alcohol use, hyperlipidemia, antiplatelet medications……( Line278-281 on Page 13) Conclusion: Make it clear that patients with depression and CBVD are actually patients who were diagnosed with depression after they had CBVD. Response: We have made sought to clarify this as follows: ' In patients with a diagnosis of depression and previous hospitalised CBVD ……'.( Line289 on Page 14)
Tables 1 and 2: Instead of CVD use CBVD, same as throughout the manuscript. Response: We have made the abbreviation 'CBVD' consistent throughout the manuscript. Response: Thanks for the advice. When we were listing letters in order, we found a problem that if we list letters in order in the table, then these letters in footnote will not be in order, thus we have decided to change letters to symbols to make it clear in Table 1 . We have also spelled out abbreviations in the footnote as follows: 'CBVD, Cerebrovascular Disease; HoNOS, Health of the Nation Outcome Scales; IMD, Index of Multiple Deprivation; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants;'. (Line182-192 on Page 8-9) We have indicated what numbers in brackets represent as follows: 'The numbers in brackets represent 95% confidence intervals (CI)'. We have also spelled out abbreviations in the footnote as follows: 'CBVD, Cerebrovascular Disease; HoNOS, Health of the Nation Outcome Scales; IMD, Index of Multiple Deprivation; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants;'( Line208-219 on Page 11) Reviewer: 3
Please leave your comments for the authors below Comments: 1. Multiple imputation by chained equations was used to impute the missing data. To benefit the readers, please provide more information of how the data were imputed. Was the same set of covariates used to impute each of variable that had missing data? What was the rational of generating 28, but not other number, imputed data sets? Response: Many thanks for highlighting this. We have updated the methods section as follows: ' Using the mi package in STATA we created 28 imputed datasets, replacing missing values through simulated values assembled from all potential covariates and outcome values. The number of complete imputed datasets was based on the rule of thumb that the number of imputations ought to be at least equal to the proportion of incomplete cases29,30.'(Line157-161 on Page 7) 2. According to the method section, 1292 patients who had a depressive disorder diagnosis between 1/1/2008 to 12/31/2017 and had CBVD prior to the depression diagnosis were included in the analyses. Patients were followed till CBVD recurrence (both fatal and non-fatal), death, or end of the study (3/31/2017). However, the mean follow-up time for the study was only 2.43 years (SD=2.31) (page 8, line 16). Please comment on the short follow-up time. Response: Since we have conducted a retrospective cohort study based on the database, the followup time was decided by the final statistical result of patient information extracted from the database. Maximum follow-up time available was 9.24 years. Differences in follow-up time were addressed using Cox regression models.
3. Patients had to have a depressive disorder diagnosis to be included in the study, but Table 1 showed that 29.5% of the patients were 'no, minor or transient changes in mood'. Please comment. Response: Thanks a lot. All the patients included in this study were diagnosed with depression. 29.5% of the patients who were 'no, minor or transient changes in mood' had less severe depression than the rest of the patients. Some of this may reflect variation in severity, some might reflect HoNOS ratings which were less contemporaneous with the depression diagnosis. We have decided to change the name of the category to 'minor or transient changes in mood' to avoid confusion. 4. How many patients died due to non-CBVD cause in the study? Response: We can clarify that 637 patients died due to non-CBVD cause in the study. 5. The method section stated that model 1 was adjusted for age and gender, and model 2 was adjusted for some more variables. However, regardless of the models, Table 2 had hazard ratios listed for every single variable. Shall model 1 only have HR available for age and gender but not the variables? Response: Many thanks for the question. Based on previous studies (6-9 below), age and gender are the most strongly and consistently associated factors, so we adjusted for age and gender in model 1. For the other variables, we have conducted a fully adjusted model ( 6. In the discussion the authors compared their findings to those of Yu S, Sibolt G and Yuan HW (page9, line 26). The comparison is not very meaningful since all the individuals involved in the authors' study had a depression diagnosis, whereas depression diagnosis wat not a requirement for patient selection in Yu, Sibolt and Yuan's studies. Response: Thanks a lot for your advice. Unfortunately, there is a dearth of literature on this topic and Yu, Sibolt and Yuan's studies were the most similar to our study we could identify. All the patients included in Yu, Sibolt and Yuan's studies were CBVD survivors, and those who were depressed were likely to have another CBVD, which indicated that depression after CBVD predicted recurrent CBVD. Thus, we have made it clearer in our text as follows: ' An interesting finding in our study was the lack of association of depression severity with CBVD recurrence, which contrasts with several previous reports of associations between post-CBVD depression with recurrent CBVD 6,8,9'(Line233-235 on Page 12) 7. The distributions of follow up time and number of medication use were highly skewed. Please present them as median and inter-quartile range instead of mean (SD). Response: Many thanks for highlighting this we have updated the follow-up time in text and the number of medications in Table 1 using median and IQR. (Table 1) FORMATTING AMENDMENTS (if any) Required amendments will be listed here; please include these changes in your revised version: 1. Corresponding author's email address mismatch: -Please ensure that your "Corresponding author's email address" in your main document and ScholarOne submission system are the same. Response: We've had a double check to ensure that the "Corresponding author's email address" in our main document and ScholarOne submission system are the same. 
No statements:
-Please embed the following statements to your main document just before your reference list: A. contributor ship statement B. competing interests C. funding D. data availability statement Response: We have embedded all the statements above to our main document before the reference list.
No Patient and Public Involvement:
-We have implemented an additional requirement to all articles to include 'Patient and Public Involvement' statement within the main text of your main document. Please refer below for more information regarding this new instruction:
Authors must include a statement in the methods section of the manuscript under the sub-heading 'Patient and Public Involvement'. This should provide a brief response to the following questions:
How was the development of the research question and outcome measures informed by patients' priorities, experience, and preferences? How did you involve patients in the design of this study? Were patients involved in the recruitment to and conduct of the study? How will the results be disseminated to study participants? For randomised controlled trials, was the burden of the intervention assessed by patients themselves? Patient advisers should also be thanked in the contributorship statement/acknowledgements. If patients and or public were not involved please state this. Response: We have included 'Patient and Public Involvement' statement within the methods section of our manuscript as follows: 'Patient and Public Involvement: A patient-led committee provides operational oversight of the CRIS resource and ensures that the proposed study has both scientific value as well as benefit for patients and carers 16,17. The project was approved by this committee with an outline of the proposed analysis, including data linkages. There was no further patient and public involvement in the design of this register-based study.'(Line163-167 on Page 7) VERSION 2 -REVIEW REVIEWER 1. For instance, the remark I made about the duration of depression, in context of authors stating that they have used data from the databases according to the date of depression diagnosis and date of CBVD recurrence, referred to the usefulness of assessing the duration of depression as the time between those timepoints, or until the final observed date for those without a recurrence. It is unnecessary that the authors interpret this remark in such way which confuses date of depression diagnosis and the onset of depression, which they do in their replies to comments in the revised paper. Therefore, stating the term ''onset/duration'' in the Limitations simply has nothing to do with my comment. It is not clear why the authors: 1) did not take into account the duration of depression in their paper, 2) why, if not doing so, did not simply and correctly state that as a limitation of their work.
2. Further on, I noted in my first review of the paper that the authors have used the term ''anticoagulant use '' and ''antipsychotic prescription'' in the Discussion of the original manuscript, and advised them to address the issue of patients' compliance by changing the term ''use'' to the term ''prescription'', a term which they had used for another group of drugs. In their reply, authors made a remark saying that they are making this change but that they ''have also sought to clarify throughout that medication is that 'recorded', as we were not using a prescribing database to ascertain this. (Line225/248 on Page 12)''. Firstly, the authors themselves have used the term prescription in the same paragraphs for different medications, as well as throughout the original (and revised) manuscript, which they shouldn't have done if they felt it did not correspond with the data they had available. Secondly, in their response to this comment authors have unfortunately revealed a bigger issue in their methodology, and that is the following: ''we were not using a prescribing database to ascertain this'', referring to actual prescription of medications they have investigated as possibly associated with the outcome of interest. This itself is another limitation, but the issue is that the authors have said the opposite throughout their paper and in Methodology. What is correct here? Finally, the issue of medication compliance still remains standing, as the authors have skipped their reply to this issue, and the issue should be noted as such in limitations.
3. Further on, authors very inappropriately input that the change they are making in Limitations is due to my remark, even though in my comment concerning limitations I have stated that the authors need to state that one of the limitations was that they did not present data on the LENGTH/DURATION of depression, which is completely different from ''onset/duration'' which they added to limitations. Please also see the point 1 above.
REVIEWER
Yue I am still confused about the results presented in Table 2 . The authors stated that Model 1 was adjusted for age and gender. I supposed this meant that model 1 only had age and gender as the independent variables and nothing else. If this is the case, it is puzzled why there were HR listed for the variables that were not in the model?
The statistical analysis section described that "Multivariate models were first adjusted for age and gender (Model I), then for ….". This sentence implied that there is a variable (or variables) of interest that the authors wanted to investigate; to do so, they first studied the effect of that variable of interest on the recurrence of CBVD by controlling for age and gender, and then followed by controlling more covariates. Is this what the authors meant to do? If not, please make the sentence more clearly.
VERSION 2 -AUTHOR RESPONSE First author
Reviewer 3:
Regarding Number of medication -Please change the label in table 1 to 'Number of medications (median(IQR))'.
Due to the skewness of number of medication use, non-parametric method such as Wilcoxon rank sum test should be used for the between group comparison. Please reflect this in the statistical analysis section and correct the p-value in Table 1 accordingly.
Response: Many thanks for highlighting this; we have changed the label in the table and also expanded the key.
We have further applied the Wilcoxon rank sum to this variable, which changed the p-value from 0.862 to 0.724 The statistical analysis section described that "Multivariate models were first adjusted for age and gender (Model I), then for ….". This sentence implied that there is a variable (or variables) of interest that the authors wanted to investigate; to do so, they first studied the effect of that variable of interest on the recurrence of CBVD by controlling for age and gender, and then followed by controlling more covariates. Is this what the authors meant to do? If not, please make the sentence more clearly.
Response: Yes, that is what we were doing; many thanks for your suggestion to make this clearer, which we have added to the methods as follows:
'Variables of interest (predictors/risk factors for CBVD reoccurrence) were examined in multivariate models: first controlling for age and gender (Model I), then controlling for age, gender, ethnic group, cohabiting status, IMD score, depressed mood and physical illness problem scores (Model II), and finally all covariates were included (Model III) to determine independent associations. ' I am still confused about the results presented in Table 2 . The authors stated that Model 1 was adjusted for age and gender. I supposed this meant that model 1 only had age and gender as the independent variables and nothing else. If this is the case, it is puzzled why there were HR listed for the variables that were not in the model?
Response:
Following on from that, we have expanded the description of the models in Table 2 and added the descriptive term 'Risk factor' as heading for the first column; the key was changed to: 'Model I -variable of interest (risk factor) controlling for age and gender.
Model II -variable of interest (risk factor) controlling for age, gender, ethnic group, cohabiting status, IMD score, depressed mood, physical illness and disability.'
Reviewer 2:
For instance, the remark I made about the duration of depression, in context of authors stating that they have used data from the databases according to the date of depression diagnosis and date of CBVD recurrence, referred to the usefulness of assessing the duration of depression as the time between those timepoints, or until the final observed date for those without a recurrence. It is unnecessary that the authors interpret this remark in such way which confuses date of depression diagnosis and the onset of depression, which they do in their replies to comments in the revised paper. Therefore, stating the term ''onset/duration'' in the Limitations simply has nothing to do with my comment. It is not clear why the authors: 1) did not take into account the duration of depression in their paper, 2) why, if not doing so, did not simply and correctly state that as a limitation of their work.
Further on, authors very inappropriately input that the change they are making in Limitations is due to my remark, even though in my comment concerning limitations I have stated that the authors need to state that one of the limitations was that they did not present data on the LENGTH/DURATION of depression, which is completely different from ''onset/duration'' which they added to limitations. Please also see the point 1 above.
Response: We would like to express our sincere apologies for misinterpreting your previous comment. We have now removed 'onset/duration' from the list or risk factors listed under the 'Third' limitation and expanded on this as a fourth limitation as follows:
'Fourth, we were unable to present data on the length/duration of depressive symptoms before patients entered the cohort. As this is a cohort under a specialist mental health service, primary care providers might have differing thresholds for referring into specialist psychiatric care.' Further on, I noted in my first review of the paper that the authors have used the term ''anticoagulant use'' and ''antipsychotic prescription'' in the Discussion of the original manuscript, and advised them to address the issue of patients' compliance by changing the term ''use'' to the term ''prescription'', a term which they had used for another group of drugs. In their reply, authors made a remark saying that they are making this change but that they ''have also sought to clarify throughout that medication is that 'recorded', as we were not using a prescribing database to ascertain this. (Line225/248 on Page 12)''. Firstly, the authors themselves have used the term prescription in the same paragraphs for different medications, as well as throughout the original (and revised) manuscript, which they shouldn't have done if they felt it did not correspond with the data they had available. Secondly, in their response to this comment authors have unfortunately revealed a bigger issue in their methodology, and that is the following: ''we were not using a prescribing database to ascertain this'', referring to actual prescription of medications they have investigated as possibly associated with the outcome of interest. This itself is another limitation, but the issue is that the authors have said the opposite throughout their paper and in Methodology. What is correct here? Finally, the issue of medication compliance still remains standing, as the authors have skipped their reply to this issue, and the issue should be noted as such in limitations.
Response: Many thanks for highlighting those inconsistencies. We are so sorry for that.
We have now removed the term 'use' throughout the manuscript and used 'prescription' throughout the manuscript to reflect important issues around compliance.
Although we did not use a pure prescribing database, prescribing of medication was ascertained both from structured fields in the source records, as well as through natural language processing.
We added to the methods: 'We further ascertained medications recorded within a time window from 6 months before to 6 months after the index date through a GATE-supported natural language processing algorithm17 21, supplemented by mentions in relevant structured fields from the record……'
We further added to the limitations:
'Fifth, while we are able to capture through free-text and structured fields which medications a patient is prescribed around index date, we have no information whether they were adhering to their medication regime of the study period.'
VERSION 3 -REVIEW REVIEWER
Yue-Fang Chang University of Pittsburgh, USA REVIEW RETURNED 15-Nov-2019
GENERAL COMMENTS
The authors have addressed my concerns appropriately.
